Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21

Investing.com - Roth/MKM has reduced its price target on Entrada Therapeutics (NASDAQ:TRDA) to $17.00 from $21.00 while maintaining a Buy rating on the stock. The stock currently trades at $5.95, down nearly 66% year-to-date, significantly below both the new price target and its 52-week high of $21.79.

The price target adjustment follows Entrada’s second-quarter 2025 results, which were reported on Wednesday. According to InvestingPro data, while the company maintains a strong balance sheet with more cash than debt, it faces challenges with rapid cash burn and declining revenues.

The research firm specifically sought clarity on ENTR-601-44 and ENTR-601-45, two assets that Roth/MKM includes in its valuation models for the biotechnology company.

Despite the lower price target, Roth/MKM expressed optimism about Entrada’s strong cash position and multiple clinical data readouts expected in 2026.

The firm acknowledged that negative sentiment currently surrounds Entrada’s stock, partly due to a lack of value-driving data catalyst events scheduled for the remainder of 2025.

In other recent news, Entrada Therapeutics has received regulatory approval to begin a new clinical study in Europe and the United Kingdom (TADAWUL:4280). The company will initiate the ELEVATE-45-201 Phase 1/2 multiple ascending dose clinical study of ENTR-601-45, targeting patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping. This study is expected to start in the third quarter of 2025 and will enroll approximately 24 ambulatory patients. The first part of the study will focus on safety and optimal dosing, while the second part will assess the drug’s efficacy and its impact on patients’ functional outcomes and quality of life. In light of these developments, analysts at H.C. Wainwright have reaffirmed their Buy rating for Entrada Therapeutics, maintaining a price target of $20.00. The analysts’ decision follows the recent regulatory approvals, which mark significant progress for the company’s clinical efforts. These developments reflect Entrada Therapeutics’ ongoing commitment to advancing treatments for DMD.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.